| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BTNL3 |
| Uniprot No | Q6UXE8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-466aa |
| 氨基酸序列 | MAFVLILVLSFYELVSGQWQVTGPGKFVQALVGEDAVFSCSLFPETSAEAMEVRFFRNQFHAVVHLYRDGEDWESKQMPQYRGRTEFVKDSIAGGRVSLRLKNITPSDIGLYGCWFSSQIYDEEATWELRVAALGSLPLISIVGYVDGGIQLLCLSSGWFPQPTAKWKGPQGQDLSSDSRANADGYSLYDVEISIIVQENAGSILCSIHLAEQSHEVESKVLIGETFFQPSPWRLASILLGLLCGALCGVVMGMIIVFFKSKGKIQAELDWRRKHGQAELRDARKHAVEVTLDPETAHPKLCVSDLKTVTHRKAPQEVPHSEKRFTRKSVVASQGFQAGKHYWEVDVGQNVGWYVGVCRDDVDRGKNNVTLSPNNGYWVLRLTTEHLYFTFNPHFISLPPSTPPTRVGVFLDYEGGTISFFNTNDQSLIYTLLTCQFEGLLRPYIQHAMYDEEKGTPIFICPVSWG |
| 预测分子量 | 52kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BTNL3重组蛋白的3篇参考文献，按文献名称、作者和摘要内容概括列出：
---
1. **文献名称**：*Structural and functional characterization of recombinant human BTNL3*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌表达系统成功纯化BTNL3胞外结构域重组蛋白，并解析其晶体结构。发现BTNL3通过特定构象与γδ T细胞受体结合，提示其在黏膜免疫中的调控作用。
---
2. **文献名称**：*BTNL3 modulates CD8+ T cell activation in colorectal cancer*
**作者**：Zhang L, et al.
**摘要**：利用哺乳动物细胞表达的BTNL3重组蛋白，发现其通过抑制CD8+ T细胞增殖和细胞因子分泌参与肿瘤免疫逃逸，为癌症免疫治疗提供潜在靶点。
---
3. **文献名称**：*Recombinant BTNL3 synergizes with PD-1 blockade to enhance antitumor immunity*
**作者**：Wang Y, et al.
**摘要**：研究在小鼠模型中验证BTNL3重组蛋白与抗PD-1抗体的联合治疗效果，显示其通过激活特定T细胞亚群显著抑制肿瘤生长，提出新型免疫联合疗法策略。
---
注：以上为模拟文献，若需真实文献，建议通过PubMed或Google Scholar以“BTNL3 recombinant protein”为关键词检索。
**Background of BTNL3 Recombinant Protein**
Butyrophilin-like 3 (BTNL3) is a member of the butyrophilin (BTN) family, a group of proteins structurally and functionally related to the B7 family of immune regulatory molecules. BTNL3 is primarily expressed in epithelial and immune cells, particularly in tissues such as the gastrointestinal tract, skin, and lymphoid organs. It plays a critical role in modulating immune responses, particularly in the regulation of γδ T cells, a subset of T lymphocytes involved in mucosal immunity, tissue homeostasis, and pathogen defense.
Structurally, BTNL3 contains immunoglobulin variable (IgV) and constant (IgC) domains, a transmembrane region, and a short cytoplasmic tail. Its extracellular IgV domain interacts with γδ T cell receptors (TCRs), influencing their activation and function. BTNL3 often forms heterodimers with BTNL1. another BTN family member, to engage specific Vγ4+ γδ T cells, thereby regulating their responses in barrier tissues. This interaction highlights its role in maintaining immune tolerance and controlling inflammation.
Recombinant BTNL3 protein is engineered for research and therapeutic applications. Produced using mammalian expression systems (e.g., HEK293 or CHO cells) or bacterial systems (e.g., *E. coli*), it retains structural integrity and biological activity. Purification methods, such as affinity chromatography, ensure high purity for functional studies. Recombinant BTNL3 is widely used to study γδ T cell biology, immune checkpoint pathways, and mechanisms underlying inflammatory diseases (e.g., colitis, psoriasis) or cancers. It also serves as a tool for developing immunotherapies targeting BTNL3-mediated signaling.
Dysregulation of BTNL3 has been linked to autoimmune disorders and cancer progression, making it a potential biomarker or therapeutic target. Ongoing research focuses on its dual roles in immune activation and suppression, as well as its interplay with other BTN family members in tissue-specific immunity.
×
